Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

[1] Balkau B(2003)The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study Diabetes Metab 29 526-532

[2] Vernay M(2003)A comparison of the prevalence of the metabolic syndrome using two proposed definitions Diabetes Care 26 575-581

[3] Mhamdi L(2003)Dietary, evolutionary, and modernizing influences on the prevalence of type 2 diabetes Annu Rev Nutr 23 345-377

[4] Novak M(2001)Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 683-689

[5] Arondel D(2002)The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2709-2716

[6] Vol S(2003)Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 414-419

[7] Tichet J(2003)New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial J Renin Angiotensin Aldosterone Syst 4 169-170

[8] Eschwege E(2004)Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity Hypertension 43 993-1002

[9] Ford ES(2004)An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes FEBS Lett 576 492-497

[10] Giles WH(2004)Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-g activity Circulation 109 2054-2057

[1] Balkau B(2003)The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study Diabetes Metab 29 526-532

[2] Vernay M(2003)A comparison of the prevalence of the metabolic syndrome using two proposed definitions Diabetes Care 26 575-581

[3] Mhamdi L(2003)Dietary, evolutionary, and modernizing influences on the prevalence of type 2 diabetes Annu Rev Nutr 23 345-377

[4] Novak M(2001)Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 683-689

[5] Arondel D(2002)The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2709-2716

[6] Vol S(2003)Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 414-419

[7] Tichet J(2003)New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial J Renin Angiotensin Aldosterone Syst 4 169-170

[8] Eschwege E(2004)Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity Hypertension 43 993-1002

[9] Ford ES(2004)An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes FEBS Lett 576 492-497

[10] Giles WH(2004)Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-g activity Circulation 109 2054-2057